<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01074554</url>
  </required_header>
  <id_info>
    <org_study_id>091103</org_study_id>
    <nct_id>NCT01074554</nct_id>
  </id_info>
  <brief_title>Trial of Antimycobacterial Therapy in Sarcoidosis</brief_title>
  <acronym>CLEAR</acronym>
  <official_title>Phase I/II Study of the Effects of Antibiotics on Sarcoidosis Pathogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Growing research from independent laboratories provide an association between mycobacteria
      and sarcoidosis. More recent immunologic and molecular studies demonstrate immune responses
      to mycobacteria virulence factors. The purpose of this study is to assess if administration
      of anti-mycobacterial drug therapy will aid in resolution of cutaneous sarcoidosis lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Independent molecular and immunologic investigations strengthen the association between
      mycobacterial antigens and sarcoidosis pathogenesis. Molecular analysis of sarcoidosis
      granulomas reveals the presence of Mycobacterium tuberculosis complex (MTB) DNA and proteins
      that are significantly absent from granulomatous controls. Mycobacterial DNA has been
      detected in cutaneous sarcoidosis lesions, in addition to systemic immune responses against
      mycobacterial antigens. Due to the association between sarcoidosis and mycobacterial
      antigens, we postulated that broad spectrum antimycobacterial therapy could lead to
      restoration of T cell function and clinical improvement of chronic cutaneous sarcoidosis
      lesions. We investigated the safety and efficacy of Concomitant Levofloxacin, Ethambutol,
      Azithromycin, and Rifampin (CLEAR) therapy among chronic cutaneous sarcoidosis subjects, with
      change in lesion diameter from baseline to completion of 8 weeks of therapy as the primary
      endpoint; we assessed for decreases in granuloma burden, if granulomas were evident upon
      histologic examination. Change in modified Sarcoidosis Activity Severity Index (SASI) was the
      secondary endpoint.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Granuloma Burden</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Number of patients with a decrease in Granuloma Burden (only in those patients having granulomas present at baseline biopsy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Modified Sarcoidosis Activity and Severity Index (SASI) at Completion of Therapy.</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Characterization of lesion severity was conducted using Modified Sarcoidosis Activity and Severity Index (SASI), measuring erythema, induration and desquamation. The modification was that the same scale was applied to any part of the body, instead of the face alone. The scale range is 0 (no problem) to 72 (very severe).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Antibiotic Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD.
All four drugs are given concomitantly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Regimen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic Regimen</intervention_name>
    <description>Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly</description>
    <arm_group_label>Antibiotic Regimen</arm_group_label>
    <other_name>Levaquin=Levofloxacin</other_name>
    <other_name>Ethambutol=Myambutol</other_name>
    <other_name>Azithromycin=Zithromax</other_name>
    <other_name>Rifampin=Rifadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Regimen</intervention_name>
    <description>lactose control tablets; one for each antibiotic with equivalent pills</description>
    <arm_group_label>Placebo Regimen</arm_group_label>
    <other_name>Lactose control tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as
             defined by the clinical presentation consistent with sarcoidosis, biopsy finding
             granulomas, and no alternative for the cause of the granulomas, such as tuberculosis

          2. Patients must have chronic cutaneous skin lesions with or without taking chronic
             therapy (corticosteroids, methotrexate (max 10mg/week), azathioprine,
             hydroxychloroquine, cyclophosphamide, minocycline, doxycycline and chloroquine), in
             which the dose has not been altered in the 2 months prior to starting the study.

          3. Subject has a diagnosis of cutaneous sarcoidosis for greater than 6 months with a
             Sarcoidosis Activity and Severity Index assessment score of at least 4. Diagnosis can
             be made by either:

               -  Skin lesions characteristic of sarcoidosis and a biopsy showing granulomas with
                  no evidence of mycobacteria, fungus, or malignancy.

               -  A biopsy that does not show granulomas, but the patient has characteristic skin
                  lesions and history of clinical features suggesting sarcoidosis (previous biopsy
                  revealing noncaseating granuloma, bilateral hilar adenopathy, erythema nodosum,
                  uveitis, raised ACE level, BAL lymphocytosis (CD4:CD8&gt;3.5), panda/lambda sign on
                  gallium scan)

               -  Accepted clinical variants include, but are not necessarily limited to the
                  following:

                    -  lupus pernio

                    -  nodular

                    -  subcutaneous

                    -  annular

                    -  angiolupoid

                    -  plaque

                    -  papular

                    -  lichenoid

                    -  psoriasiform

               -  For purposes of this study &quot;moderate to severe cutaneous sarcoidosis&quot; is defined
                  as the presence of sarcoidal skin lesions with any of the following features:

                    -  At least 5 easily visible facial lesions, or

                    -  Disease which involves &gt; 3% BSA, or

                    -  Disease which confers functional impairment (e.g. nasal or visual field
                       obstruction), or

                    -  Disease which confers significant symptoms of itching and/or pain.

          4. If female, subject is either not of childbearing potential, defined as postmenopausal
             for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral
             oophorectomy, or hysterectomy), or is using one of the following methods of birth
             control for the duration of the study and 90 days after study completion:

               -  condoms, sponge, foams, jellies, diaphragm, or intrauterine device

               -  contraceptives (oral or parenteral) for three months prior to study drug
                  administration

               -  a vasectomized sole partner

               -  Females of childbearing potential must have a negative serum pregnancy test at
                  screening visit.

        Exclusion Criteria:

          1. No consent/inability to obtain consent.

          2. Age less than 18 years of age.

          3. Inability to obtain biopsy or draw blood.

          4. CPK, ALT or AST &gt;5 times upper limit of normal (ULN)

          5. Pregnancy or breast feeding.

          6. Current use of medications metabolized by rifampin (See Appendix).

          7. Allergy to macrolides, quinolones or rifamycins.

          8. Visual Impairment as defined by differentiating colors.

          9. Family or personal history of long QT syndromes.

         10. Patients receiving another interventional investigational drug within the 30 days
             prior to dosing

         11. Use of any investigational medication within the past 28 days prior to study
             enrollment.

         12. Subject has been hospitalized for infection or received IV antibiotics within the
             previous 2 months prior to baseline.

         13. Subject has a history of tuberculosis at anytime or close contact with a person with
             active tuberculosis within the previous 6 months, or persistent or active infections
             requiring hospitalization or treatment with IV antibiotics, IV antiretrovirals, or IV
             antifungals within 30 days of baseline, OR oral antibiotics, antivirals, or
             antifungals for purpose of treating infection, within 14 days of baseline.

         14. Evidence of other active skin diseases or skin infections during screening that may
             interfere with evaluation of sarcoidosis.

         15. Subject has an active infection requiring systemic antibiotics at time of screening

         16. Subject has a history of listeriosis, treated or untreated tuberculosis, exposure to
             individuals with tuberculosis.

         17. Subject has a variant of sarcoidosis that is not amenable to study evaluation, in the
             absence of chronic indurated lesions, such as:

               -  Acute, &quot;benign&quot; sarcoid associated with erythema nodosum

               -  Acute iritis

               -  Ichthyosiform sarcoidosis

               -  Hypo- or hyperpigmented macular sarcoidosis

               -  Ulcerative sarcoidosis

               -  Erythroderma

               -  Alopecia

         18. Patients otherwise unsuitable for participation in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wonder P Drake, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanerbilt University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <results_first_submitted>October 26, 2012</results_first_submitted>
  <results_first_submitted_qc>September 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 27, 2016</results_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Wonder Drake</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>sarcoidosis</keyword>
  <keyword>mycobacteria</keyword>
  <keyword>cutaneous lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One patient who was randomized to the CLEAR regimen did not have lesions compatible with sarcoidosis at baseline. This patient did not proceed with study participation and was removed from number of patients that started the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Antibiotics</title>
          <description>This study will compare the effects of antibiotics or placebo on resolution of cutaneous sarcoidosis lesions.</description>
        </group>
        <group group_id="P2">
          <title>Lactose Tablets</title>
          <description>Patients who are randomized to control arm will receive an equivalent number of lactose tablets.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Antibiotics</title>
          <description>This study will compare the effects of antibiotics or placebo on resolution of cutaneous sarcoidosis lesions.</description>
        </group>
        <group group_id="B2">
          <title>Lactose Tablets</title>
          <description>Patients who are randomized to control arm will receive an equivalent number of lactose tablets.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="41" upper_limit="60"/>
                    <measurement group_id="B2" value="53" lower_limit="42" upper_limit="57"/>
                    <measurement group_id="B3" value="53" lower_limit="42" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions</title>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotic Regimen</title>
            <description>The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD.
All four drugs are given concomitantly.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Regimen</title>
            <description>The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions</title>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="14"/>
                    <measurement group_id="O2" value="0.07" spread="32."/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Granuloma Burden</title>
        <description>Number of patients with a decrease in Granuloma Burden (only in those patients having granulomas present at baseline biopsy)</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotic Regimen</title>
            <description>The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD.
All four drugs are given concomitantly.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Regimen</title>
            <description>The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills</description>
          </group>
        </group_list>
        <measure>
          <title>Granuloma Burden</title>
          <description>Number of patients with a decrease in Granuloma Burden (only in those patients having granulomas present at baseline biopsy)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Modified Sarcoidosis Activity and Severity Index (SASI) at Completion of Therapy.</title>
        <description>Characterization of lesion severity was conducted using Modified Sarcoidosis Activity and Severity Index (SASI), measuring erythema, induration and desquamation. The modification was that the same scale was applied to any part of the body, instead of the face alone. The scale range is 0 (no problem) to 72 (very severe).</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotic Regimen</title>
            <description>The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD.
All four drugs are given concomitantly.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Regimen</title>
            <description>The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Modified Sarcoidosis Activity and Severity Index (SASI) at Completion of Therapy.</title>
          <description>Characterization of lesion severity was conducted using Modified Sarcoidosis Activity and Severity Index (SASI), measuring erythema, induration and desquamation. The modification was that the same scale was applied to any part of the body, instead of the face alone. The scale range is 0 (no problem) to 72 (very severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="2.5"/>
                    <measurement group_id="O2" value="-0.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Antibiotics</title>
          <description>This study will compare the effects of antibiotics or placebo on resolution of cutaneous sarcoidosis lesions.</description>
        </group>
        <group group_id="E2">
          <title>Lactose Tablets</title>
          <description>Patients who are randomized to control arm will receive an equivalent number of lactose tablets.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>snomed</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="SNOMED CT">insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title vocab="SNOMED CT">pill burden</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>joint pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Wonder Drake</name_or_title>
      <organization>Vanderbilt University School of Medicine</organization>
      <phone>615-322-2035</phone>
      <email>wonder.drake@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

